Cancer, San Francisco, Teke discussed on Important, Not Important


And now our now you have these modified cells that seems wonderful advancement will I can tell you, you know, me personally, I like it for two things one because I do these experiments. Anything that makes the experiment that I do go quicker means one, you know, I have more free time, but also means that we can do more experiments more quickly. He anyo in increase the pace of development of these therapies. So we're excited about that. And I think we're all the the second thing is that if it's easier for us to do in the lab, then that means that it should be easier and cheaper and simpler to do in the clinic as well. Right? There's going to be people going away to does supply. All cancers. So what, what who does this treatment apply to? What sort of cancers does this? Does this make sense for? Yeah, yeah. And so I think that case, you know, I I, I live in the in San Francisco, so it's hard to not. You start using all the the, the buzzwords, that the Teke invoice news, but you, we think of this more as a as a platform, these these immune cells, T-cells, they can be made to be specific for many different types of cancers they can. We can if we can modify them very quickly, we can modify them in just the right way to attack this. You know this type of tumor, say prostate cancer or colon cancer in. So rather than using you trying to find a chemotherapy that works against every single type of cancer. If it's really easy and really fast to modify these immune cells to make them the right type of. Immune cell for an individual cancer, and then to be an individual type of cancer or potentially even in the under the heading of personalized medicine in individual patient's tumor. If fast enough and easy enough, we can make the municipals have just the right modifications so that they attack that patients or that type of tumor. That's the that's the grill will little bit right, which is instead of trying seven different things in saying, well, this worked on this cancer in this person, but it didn't work on this person with this cancer. It's going this, this person's type of this cancer as we can now move on these things. So quick that we can act on the minimum much more personalized ineffective way is, is that kind of what we're you're aiming for? Yeah, no, I think that's exactly kind of kind of the goal. We've started by making the process of doing that modification, simpler easier. You know the next steps that knew it for our land for many. Other labs.

Coming up next